Global Reach Health News

October 22, 2021

Cancer Medicine Pepaxto Withdrawn from Market

October 22, 2021 – Oncopeptides will withdraw Pepaxto® (melphalan flufenamide) from the United States market after a post-marketing clinical trial raised safety concerns
October 22, 2021

FDA Approves Expanded Indications for Cyltezo

October 22, 2021 – Cyltezo® (adalimumab-adbm – Boehringer Ingelheim) has received U.S. FDA approval to reduce the signs and symptoms of moderately to severely